Trial Profile

Phase III trial of PRN2246 in relapsing and progressive forms of Multiple Sclerosis

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 01 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tolebrutinib (Primary)
Indications Multiple sclerosis
Focus Registrational; Therapeutic Use

Most Recent Events

12 Mar 2020 New trial record
10 Mar 2020 According to a Principia Biopharma media release, the company expects to initiate this trial in the middle of 2020.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com